News
Along the Pike
July 15, 2004
Volume 10,
Issue 2
Center for Drug Evaluation and Research
- FDA's "Critical
Path" report identifies research gaps: Drug
development not keeping pace with basic discoveries By
Janet Woodcock, M.D.
- Regulatory Science, Review Enhancement
projects By Rosa Perez
- CDER 2003 Report to the Nation
available online, in print By Norman J. Oliver
- Dr. Seligman works with CERTs to
optimize use of therapeutics By Patrick E. Clarke
- OGD lists Paragraph IV application
dates
- Pike's Puzzler: Medical scramble
By Tony Chite, P.D.
- CDER launches new easy-to-use drug
information Web site By Monica Unger
- Crime prevention seminar emphasizes
personal safety, security By Patrick E. Clarke
- Frequently asked questions about OTC
drugs on Web By Ron Wilson
- Office of New Drug Chemistry director
has mandate for change By Patrick E. Clarke
- CDER employees enjoy picnic
weather, tour White Oak grounds, buildings
- Pharm/Tox Corner: Spring retreat
focuses on current scientific, regulatory issues By
Gary P. Bond, Ph.D., DABT
- Dr. Jenkins provides pharm/tox retreat
with update on Office of New Drugs By Gary P.
Bond, Ph.D., DABT
- Biologics Corner: Compliance's
Therapeutics Facilities Review Branch keeps pace By
Patrick E. Clarke
- 1st step taken to recognize
role of emerging manufacturing technologies
- Joe's Notebook: Cancer death
rates, incidence decline
- Editorial Board
Return to Index
By Janet Woodcock, M.D.
FDA’s report, Innovation or Stagnation?--Challenge
and Opportunity on the Critical Path to New Medical
Products, provides our analysis of the “pipeline
problem.”
There is a slowdown-instead of an expected
acceleration-in innovative medical therapies reaching
patients. The medical product development path is becoming
increasingly challenging, inefficient and costly.
As a consequence, our mission to ensure the availability
of safe and effective medical treatments for Americans that
take advantage of the latest science is becoming
compromised.
In our view, the applied sciences for product development
have failed to keep pace with the tremendous advances in the
basic sciences. New science is not being used to guide the
development process in the same way that it is accelerating
the discovery process.
To focus the attention of the public, academic
researchers, funding agencies and industry, our report
identifies:
-
The critical path for product
development from design and discovery to commercial
marketing.
-
The scientific and technical
dimensions of the critical path.
-
The three types of research that
support the critical path.
Critical path
An idealized “critical path” encompasses the
development processes for drugs, biologics and devices. The
critical path begins after basic research provides candidate
products for development. These products then face
successively more rigorous evaluation steps along the path,
including:
A striking feature of this path is the difficulty, at any
point, of predicting ultimate success with a novel
candidate. Recent biomedical research breakthroughs have not
improved our ability to identify successful candidates.
Critical path dimensions
From the earliest phases of preclinical work to
commercialization, developers must manage in these three
dimensions:
-showing that a
product is adequately safe for each stage of
development.
Demonstrating medical utility-
showing
a new product will actually benefit people.
Industrialization-
turning a
laboratory concept into a consistent and
well-characterized medical product that can be mass
produced.
The traditional tools used to assess product
safety-animal toxicology and outcomes from human
studies-have changed little over many decades and have
largely not benefited from recent gains in scientific
knowledge.
Better tools are needed to identify products that will
prove clinically useful and eliminate impending failures
more efficiently and earlier in the development process.
The current drug discovery process, based on in-vitro
screening techniques and animal models of often poorly
understood clinical relevance, is fundamentally unable to
identify candidates with a high probability of
effectiveness. Reaching a more systemic and dynamic
understanding of human disease will require major additional
scientific efforts as well as significant advances in
bioinformatics.
The challenges involved in successful industrialization
are complex, though highly underrated in the scientific
community. Problems in physical design, characterization,
manufacturing scale-up and quality control routinely derail
or delay development programs and keep needed treatments
from patients.
Critical path research
These different types of research support medical product
development:
is directed toward
a fundamental understanding of biology and disease
processes. It provides the foundation for product
development.
Translational research
is concerned
with moving basic discoveries from concept into clinical
evaluation and is often product or disease specific.
Critical path research
is directed
toward improve the medical product development process
itself by establishing new evaluation tools.
FDA role
While the biomedical research community has widened its
efforts to include translational research, in our report, we
call for a new focus on critical path research.
Together with academia, patient groups, industry and
other government agencies, we need to embark on an
aggressive, collaborative research effort to create a new
generation of performance standards and predictive tools
that will provide better answers about the safety and
effectiveness of investigational products, faster and with
more certainty.
We at FDA are uniquely suited to take a major role in
this effort because of our experience overseeing medical
product development, assessment and manufacturing/marketing;
our vast clinical and animal databases; and our close
interactions with all the major players in the critical path
process
This initiative is not a fundamental departure for us,
but rather builds on our proven best practices for
developing industry guidance and expediting the availability
of promising medical technologies.
The next steps in this initiative include a series of
workshops and meetings to start development of a National
Critical Path Opportunities list and to identify the key
priorities.
The full report and a link to provide input and comments
to the National Critical Path Opportunities List is
available at http://www.fda.gov/oc/initiatives/criticalpath.
Janet Woodcock, the acting deputy
commissioner for operations, directed the preparation of the
report.
Return to Index
By Rosa Perez
Regulatory Science and Review Enhancement projects are
funded by the Center Director’s Office and explore
approaches, methods or data that could potentially enhance
the quality or efficiency of the drug review process or the
design and evaluation of clinical or non-clinical protocols.
Directions for submitting concept papers for new
proposals or supplemental funding for current RSR projects
are on CDER’s intranet at http://cdernet.cder.fda.gov/ocd/rsr.htm.
The principal investigators for current RSR projects are
presenting their research findings every third Tuesday at
1:30 p.m. The presentations began April 20 and will continue
through the summer to Jan. 25.
Please join your colleagues in the Parklawn Building’s
Potomac Conference Room on the 3rd Floor. Each presentation
will be for 20 minutes with 10 minutes for questions and
answers.
The schedule, the project titles and principal
investigators are:
April 20
“Estimating the background rates of joint
symptoms/conditions in the pediatric population,” Eileen
Navarro.
“Disseminating new CDER safety information: evaluation
of the effectiveness of MedWatch-e-mail notification to
pharmacy healthcare professionals,” Norman S. Marks.
June 15
“Application of classification and regression tree
(CART) statistical models for the identification of clinical
factors associated with drug-specific adverse events,” Allen
Brinker.
“Statistical issues in design and analysis of drug
abuse study,” Yi Tsong.
July 20
“Evaluation of the effect of demographic factors on the
QT interval and modeling of baseline variations in the QT
Interval on QT altering drugs,” Sam Haidar. (cancelled)
“Evaluation of the time-course of drug effect on QTc
interval and the implications of delayed response on the
correlation between drug concentration and QT prolongation,”
Sam Haidar. (cancelled)
“Flexible designs for clinical studies,” James
Hung.
August 17
“Population approach in drug development and review
process: Study design and execution, data analysis, results
reporting, and the impact on labeling-survey-based FDA
experience and future recommendations,” He Sun.
“Dosing of methylphenidate in attention deficit
hyperactivity disorder (ADHD) in children based upon
pharmacokinetic/pharmacodynamic (PK/PD) modeling
incorporating effects of tolerance, body size, formulation,
and food via trial simulation,” Ronald Kavanagh.
“A systematic approach to improve methods of hepatic
impairment,” Vanitha Sekar.
September 21
“Proper dosage adjustment in subpopulations,” He
Sun.
“Requirement of adults-to-children bridging studies,”
He Sun.
“Development of an Integrated in vitro/in vivo PK/PD
model for HIV therapy: Prediction of the potential benefit
of sub-therapeutic ritonavir dose as a pharmacokinetic
boosting agent for other HIV protease inhibitors,” Jenny
H. Zheng.
October 19
“Standardization of liposomal drug product quality,” Brian
Booth.
“Evaluation of hypotheses-driven methods for functional
genomic oncology studies,” Ning Li.
“Design and power consideration of pharmacogenomics
studies,” Sue-Jane Wang.
November 16
“Determination of the time to onset of therapeutic
response for psychiatric drugs,” Robert Levin.
“Evaluating biomarkers as surrogate endpoints using
sensitivity and specificity analyses,” Rajeshwari
Sridhara.
December 21
“The impact of risk management programs on the practice
of pharmacy,” Lauren Lee.
“Identification of immunotoxic drugs using standard
non-clinical toxicology studies,” Lynnda Reid.
“Utility of multiple event time analysis methods for
evaluation of drug safety and efficacy in new drug
applications,” Sue-Jane Wang.
January 25
“Screening clinical drug-drug interactions using
population pharmacokinetic approach,” He Sun.
“Criteria used in the Approval of Alternate Modes of
Administration of Oral Dosage Forms in Special Populations
i.e., Pediatric and Elderly Patients,” Suresh
Doddapaneni.
“Optimization of dosage regimen based on assessment of
toxicity and synergism of efficacy of irinotecan
hydrochloride (CPT-11) and 5-fluorouracil/leucovorin with
population PK/PD Modeling,” John Duan.
Rosa Perez is the RSR project manager in
the Office of Executive Programs.
Return to Index
By Norman J. Oliver
The Center’s report on its performance for 2003 is now
available in a printed version as well as on the Internet.
The report has 1995-2003 performance statistics, program
descriptions and major initiatives. While they last, you can
pick up printed copies from the Medical Library and its
branches or from OTCOM in Parklawn Room 12B-31.
If you’re not in Parklawn Building, you can send me an
e-mail at olivern@cder.fda.gov
for delivery by mail or distribution.
Online versions and slides of the charts and graphs are
available on CDER’s Website at:
http://www.fda.gov/cder/reports/rtn/2003/rtn2003.pdf.
HTML:
http://www.fda.gov/cder/reports/rtn/2003/rtn2003.htm.
Slides:
http://www.fda.gov/cder/reports/rtn/2003/rtn2003.ppt.
Return to Index
By Patrick E. Clarke
CDER’s Paul Seligman, M.D., is one of two FDA
members on the steering committee for the Centers for
Education and Research on Therapeutics. Dr. Seligman is the
director of CDER’s Office of Pharmacoepidemiology and
Statistical Sciences. The other current FDA representative
on the steering committee is Susan Gardner, Ph.D.,
from the Center for Devices and Radiological Health.
CERTs, administered by the Agency for Healthcare Research
and Quality in consultation with FDA and other HHS agencies,
is composed of seven academic centers. The research agenda
is led by the national steering committee that includes
representative leaders in health care, public health,
government and industry.
“CERTs continues to have broad representation on the
steering committee from FDA, as CDER, CBER and CDRH have
been represented,” Dr. Seligman said.
The steering committee works to shape and support the
CERTs mission to conduct research and provide education in
order to advance the optimal use of drugs, medical devices
and biological products.
Over the past two years CERTs has sponsored a series of
multi-disciplinary workshops, called the Risk Series,
focusing on risk communication, risk management, benefit
assessment and working with the media. Each workshop
included 45 to 50 invitees representing government agencies,
medical and professional societies, universities,
pharmaceutical companies and consumers.
“The idea was to talk about key issues and to identify
gaps or areas where further research is needed. A number of
publications, some still in press, have been generated by
this series-and recommendations from the series can serve as
a guide as to where research resources should go,” Dr.
Seligman said.
At a recent quarterly CERTs steering committee meeting,
the discussion was focused on a series of strategic
initiatives planned by the organization, Dr. Seligman said.
Among the top CERTs strategic initiatives that were
identified during the meeting were:
-
Following up on the Risk Series
recommendations.
-
Examining the impact of the Medicare
Modernization Act and its implications on the
availability of medications and possible risks and
benefits of the new law.
-
Continuing to focus on improving the
safety of marketed therapeutics, including consideration
for developing a national problem list of therapeutics.
-
Improving the on-going educational
progress and curriculum development for health care
providers and recognizing that doctors and pharmacists
play a critical role in the risk-benefit equation.
-
Evaluating the impact of computerized
physician order entry systems, where rather than writing
a prescription, the doctor just enters it right into a
computer.
“All the initiatives fit very nicely into FDA’s
strategic initiatives and are supportive of what we’re
trying to do at an Agency level,” Dr. Seligman said. “With
computerized physician order entry systems being
increasingly used in hospitals and in-patient settings, it
is vital to understand how well they are being accepted and
used, and whether we are realizing their potential to reduce
medical errors. As we continue to strive to improve the
quality of health care by improving the safe use of all
medical products, I expect that the CERTs will play an
increasing role in defining best practices and assessing the
impact of risk management efforts, regulatory guidance and
legislation on quality.”
Return to Index
CDER’s Office of Generic Drugs has begun providing more
information to the public to help generic drug applicants
determine if they are eligible for 180-day marketing
exclusivity for their products.
In response to two citizen petitions, the OGD Web site
will disclose the submission date for the first
substantially complete generic drug application containing a
challenge to a patent listed for the innovator drug.
Application with this “Paragraph IV” patent
certification could be eligible for 180 days of marketing
exclusivity if approved and the patent challenge is upheld.
This 180-day marketing exclusivity is an effective
incentive for generic drug development provided under the
Hatch-Waxman Amendments to the Federal Food Drug and
Cosmetic Act.
The list includes the name of the drug product, dosage
form, strength (subject of Paragraph IV certification),
reference listed drug and the date on which the first
substantially complete generic drug application was
submitted. FDA will not disclose the identity of the
applicant.
By displaying the submission date along with the trade
and generic name of the drug, its dosage form, and the
strengths of the drug products, the Agency will provide a
fairer, more transparent way for all interested parties to
gain access to this information. With better, more
transparent information, generic manufacturers will be able
to plan their development of additional generic products
more effectively. The list can be found at http://www.fda.gov/cder/ogd/ppiv.htm.
Return to Index
:
Medical scramble
By Tony Chite, P.D.
Unscramble the letters below to spell a medical term:
1. SAIMANE
2. MARGOONS
3. REGOITV
4. USEAAN
5. VUJCCIIISTTONN
6. SHAR
7. MORTER
Key: 1. amnesia; 2. sonogram; 3. vertigo; 4. nausea; 5.
conjunctivitis; 6. rash; 7. tremor
Tony Chite is a pharmacist and CSO with
the Division of Information Disclosure Policy.
Return to Index
By Monica Unger
Drugs@FDA is the first publicly available Internet
resource to offer a comprehensive overview of a drug product’s
approval history.
As part of FDA’s continuing efforts to see that
patients and consumers have the information they need to
make informed choices, the searchable database includes
information on approved prescription drugs, some
over-the-counter drugs and discontinued drugs.
Drugs@FDA makes all drug approval information available
on one site so that you no longer have to visit several CDER
Web pages for information on brand-name and generic drugs.
The database incorporates information from other parts of
CDER’s Web site, including consumer information sheets,
medication guides, labeling and other information for
patients. Eventually information on recalls, warnings and
drug shortages will also be included.
You can easily search or browse this site by drug name or
active ingredient to retrieve a complete approval history
and accompanying documents for a particular drug product.
For many drugs approved in 1998 or later, these documents
include the approval letter, labeling and reviews.
You can also find out if therapeutic equivalents exist
including generics for brand-name drugs.
Drugs@FDA can be used in other ways. For example, you
can:
-
Get the latest FDA information,
including consumer-focused information like Medication
Guides, for drugs you have been prescribed or that your
doctor is considering.
-
Identify therapeutically equivalent
drugs for prescription medicines
-
Identify alternative OTC drugs with the
same active ingredient.
-
Determine whether generic equivalents
exist for a brand-name drug.
You can access the site by clicking on Drugs@FDA under
Quick Info Links on the top right on CDER’s home page (http://www.fda.gov/cder/).
The Division of Library and Information Services in the
Office of Training and Communications developed Drugs@FDA.
The developers were Paul Stauffer, Sally Winthrop, Bill
Woodard and I, under guidance from Carol Cavanaugh, the
division director. A contractor provided programming
services for the project. We would very much like to hear
from you as you use the site. You can send us feedback by
clicking on the “Contact Us” link at the top of the
Drugs@FDA home page.
Monica Unger is the project manager for
Drugs@FDA.
Return to Index
By Patrick E. Clarke
The Program Support Center sponsored a Crime Prevention
Seminar on May 11. Members from the Department of Health and
Human Services Federal Protective Service conducted the
program.
“Preventing crime starts with you,” said Mary E.
Brown, a physical security specialist. “Know what’s
going on around you, be aware of your surroundings.” She
also emphasized the need to challenge people you are not
familiar with-not in an aggressive manner-but just with a
simple, “Can I help you?” Brown pointed out that women
often don’t lock their purses in their desks when they
leave their offices-and they should. “And I’ve seen too
many people who wear their best jewelry to work. That’s
just not a good idea,” she said.
David Hall, chief of security at Parklawn,
stressed that the guards should be called first regarding
any incident at (301) 443-4144. Then it can be determined if
FPS is to be called.
James Ward, physical security specialist, then
took the podium. “If you don’t get anything else out of
this seminar, take down our phone number - 202 708-1111,”
Ward said. Ward pointed out that not only valuables, but
information can be stolen. So, be sure to log off your
computers when leaving the workplace for extended periods of
time.
He also suggested keeping your personal keys locked up
during the workday and carrying your office keys on a
separate ring. “And never mark your keys with a label,”
Ward said. “Identify your keys by a distinctive key ring.”
Ward also explained the concept of crime prevention through
environmental design. “For example, if your coat rack is
near to a door, move it to another location because it’s
too easy for a coat to be snatched if it’s near a door,”
Ward said. “Another example is if you work in cubicles,
make sure at least two workstations are in a position where
employees can monitor entrances and exits,” Ward said.
The seminar concluded with a bomb-detection demonstration
by K-9 Susie, a golden retriever, and one of 23 sniffer dogs
in FPS.
Return to Index
By Ron Wilson
Small pharmaceutical businesses now have a resource for
questions about the over-the-counter drug review process.
OTC drugs and the OTC review drug process are a major
interest of small pharmaceutical businesses.
David Hilfiker of the Division OTC Drug Products
and Mitch Weitzman of the Office of Regulatory Policy
worked with OTCOM’s Small Business Assistance to develop a
Q&A document on OTC Drugs that provides basic
definitions to OTC terms and information about marketing an
OTC drug product.
The document helps explain basic questions about the
different routes to OTC marketing: monograph,
time-and-extent application, Rx-to-OTC Switch or new or
generic drug application.
This will not only be helpful to small pharmaceutical
businesses but other stakeholders who are unfamiliar with
the OTC drug process. The resource can be found on the Small
Business Web site at http://www.fda.gov/cder/about/smallbiz/default.htm.
Ron Wilson heads CDER’s Small Business
Assistance in OTCOM.
Return to Index
By Patrick E. Clarke
The Office of New Drug Chemistry is scheduled to move to
the White Oak campus in 2005 and anticipates a
reorganization as well.
“I’m hoping that we will have a new organizational
structure to support the new, reengineered chemistry,
manufacturing and control review practices by then,” said Moheb
Nasr, Ph.D., ONDC’s permanent director. Dr. Nasr had
served as acting director for six months, however, and has
some clear mandates and an expectation for change within the
office.
“Quality Management System is a systems approach that
will be integrated gradually into the chemistry,
manufacturing and controls review functions,” Dr. Nasr
said. The FDA Management Council has endorsed the quality
document drafted by the Good Manufacturing Practices
Steering Committee, according to Dr. Nasr.
“We’ll be starting with question-based, CMC peer
reviews. When the review is completed by ONDC reviewing
scientists, a presentation will be made for representative
drug applications before CDER scientists. The focus will be
to evaluate the quality of the review, to provide input on
the critical aspects of the review and to learn how to
utilize risk-benefit-analysis in CMC review,” Dr. Nasr
said.
As the feedback will be coming from peers, it’s
expected that it will be received more positively. “We’ve
already started this program and we have a plan for the rest
of the year,” Dr. Nasr said.
In addition to quality systems, Dr. Nasr anticipates that
input into reengineering the CMC review function will come
in part as a result of consultations with regulatory bodies.
“I’ll be discussing ONDC review practices with other
regulatory agencies throughout the world,” Dr. Nasr said.
He met with Canadian officials in March and was on extended
travel throughout Europe to discuss and evaluate their CMC
review practices.
“We are trying to focus our resources on the review of
critical aspects of CMC submissions rather than reviewing
everything in the drug application. The idea is to achieve
timely, high-quality science and risk-based CMC reviews
within our existing resources,” Dr. Nasr said.
Dr. Nasr also will be looking to add personnel to the 125
chemists and pharmaceutical scientists he is currently
responsible for. “Recruiting is a key area for this
office. We’re looking for industrial pharmacists,
pharmaceutical engineers, analytical chemists and
specialists in special dosage forms and delivery
systems-areas where we need more expertise,” Dr. Nasr
said.
The problem with making some of the changes Dr. Nasr
envisions is a very heavy workload. “We deal with about
1,700 supplemental NDAs a year in addition to NDAs, INDs and
industry meetings. The workload keeps increasing every time
a new application is approved while our resources don’t
increase. We either get more resources, change the way we do
business or both,” Dr. Nasr said.
As a former professor and chemistry department chair at
Lindenwood University in St. Charles, Mo., Dr. Nasr is a
strong advocate for research. “I think integrating more
research into our reviews is critical and helps our
reviewers stay at the cutting edge of science. In fact, I
don’t think we provide enough research opportunities and
professional development to assist our reviewing scientists
in career development,” Dr. Nasr said.
Ultimately, Dr. Nasr would “Like to change the way we
conduct CMC review in ONDC to improve the quality of the
work environment.”
Dr. Nasr’s management style is a combination of direct
involvement and delegation. “I like to be hands-on in
addressing science and research issues, but I also rely on
our senior staff that have more regulatory experience than I
do,” Dr. Nasr said.
“And I take a personal interest in every staff member.
I feel responsible for addressing everyone’s needs, so my
door is always open,” Dr. Nasr said.
Dr. Nasr began working with the federal government in
1989 as a science advisor for the Division of Drug Analysis,
which later became the Division of Testing and Applied
Analytical Development DTAAD. He took a full-time position
with DTAAD as a research chemist in 1991.
Dr. Nasr obtained his bachelor of science degree in
pharmacy and his master of science in pharmaceutical
analysis from the University of Cairo’s College of
Pharmacy in Egypt and his doctorate in chemistry from the
University of Minnesota in Minneapolis. He has been the
co-investigator and co-author of over 35 major research
studies.
Return to Index
Center employees attended a celebration of CDER at the
new White Oak campus on the afternoon of May 12. Warm
weather greeted picnickers who had an opportunity to
socialize and try several games.
A highlight was the opportunity to tour the Center’s
office space while it was still under construction. Many
also toured the completed Life Sciences Building that houses
the Office of Testing and Research’s laboratories.
The official committee for the event consisted of:
-
Office of Executive Programs: Tanya
L. Abbott, Deborah J. Henderson (chair), Justina
A. Molzon, Vikki S. Kinsey.
-
Office of Management: Eileen Cole.
-
Office of New Drugs: Rene Kimzey,
Sandra L. Kweder, Barbara J. Townsend.
-
Office of Pharmaceutical Science: Ted
M. Sherwood.
-
Office of Pharmacoepidemiology and
Statistical Science: Ruth Davi, Cyndy Kornegay,
Martha O’Connor.
-
Office of Training and
Communications: John Friel, Nancy D. Smith.
“However, there were a number of very busy
subcommittees and a multitude of other individuals who made
the event happen, including some who actually contributed
more than some of the committee members,” Debbie Henderson
said.
You can see photos of the new facilities and construction
progress at on FDA’s intranet at
http://intranet.fda.gov/ofacs/white_oak.
Return to Index
Spring retreat focuses on current scientific, regulatory
issues
By Gary P. Bond, Ph.D., DABT
The semiannual scientific retreat for CDER’s
pharmacology and toxicology reviewers, held May 27, focused
on screening INDs, phospholipidosis, evaluating the abuse
potential of drugs in development, 505(b)(2) applications,
product labeling, routes of administration and an update of
activities (below)
from the Office of New Drugs.
David Jacobson-Kram, Ph.D., DABT, OND’s
associate director for pharmacology and toxicology, shared a
brief overview of screening INDs, which aim at facilitating
the drug development screening process at the front end,
prior to more extensive, time-consuming and expensive
non-clinical and clinical testing. He discussed the
microdose IND, exploratory IND and facilitated IND.
The keynote address, “Phospholipidosis: Why are we
interested?” was presented by Lawrence F. Sancilio,
Ph.D., of the Division of Pulmonary and Allergy Drug
Products. Phospholipidosis is a condition in which there is
an excess accumulation of fatty molecules called
phospholipids in tissues due to alteration of their
synthesis and/or metabolism.
This is seen in the fatal Niemann-Pick disease in
children and with toxicity associated with
phospholipidosis-inducing drugs. A working group has been
established to determine from the FDA compound database
whether there is a direct correlation between
phospholipidosis and clinical toxicity. This is an area that
is of great interest both to the FDA and to the
pharmaceutical Industry.
Evaluating drug abuse potential
Katherine Bonson, Ph.D., from CDER’s Controlled
Substance Staff, discussed how drugs are assessed for abuse
potential during the drug development process. When an NDA
is submitted, both the Food, Drug and Cosmetic Act and the
Controlled Substances Act require an abuse potential
assessment. In evaluating whether a drug is likely to be
abused, biochemical and behavioral data from animals and
humans are reviewed, which may lead to a recommendation for
scheduling under the Controlled Substances Act. Review
divisions can consult with the Controlled Substance Staff at
any time during the IND or NDA review of a drug with central
nervous system activity.
505(b)(2) applications
Chuck Resnick, Ph.D., Division of Cardio-Renal
Drug Products, discussed the reason for this route to
approval for a new drug and our review responsibilities. The
505(b)(2) application allows sponsors who do not have a
right of reference to all the data needed for an approval to
rely on the Agency’s findings of safety and efficacy for
an approved drug or on published literature, rather than
conduct their own studies.
These applications differ from generic drug applications,
which can only be approved for drugs identical to a
reference listed drug in terms of active ingredient,
bioavailability and conditions of use, or for drugs that
differ from a reference listed drug in ways that do not
require additional clinical studies (other than
bioequivalence) to establish safety and efficacy.
The 505(b)(2) applications can be approved for drugs that
differ from an approved drug in ways that do require
additional clinical trials. Dr. Resnick discussed several
other issues with these applications including patent
exclusivity and submission data requirements.
Guidance on writing product labeling
Jeri El-Hage, Ph.D., Division of Metabolic and
Endocrine Drug Products, reviewed the specific requirements
on content and format of labeling for human prescription
drugs. She emphasized that we should carefully review
statements about the mechanism of action and receptor
selectivity in the clinical pharmacology section because
this information is generally derived from non-clinical
pharmacology studies and is often used to make marketing
claims.
She discussed recommendations for writing an animal
pharmacology section for drugs approved under the Animal
Efficacy Rule (Subpart H) and an animal toxicology section
for toxicities observed in animals but not clinically
monitorable, such as drug-induced vasculitis and central or
peripheral neuropathy.
Dr. El-Hage referred reviewers to the regulations,
examples of approved labels for the particular issues such
as boxed warnings based on toxicity data and other CDER
resources for consultation. She discussed the guidance on
the specific information such as doses studied that should
be provided to improve consistency in the non-clinical
labeling sections.
Routes of administration
Inhalation studies and non-clinical safety
assessments. I shared the special considerations that
are part of safety assessments for inhaled drugs. Among
several important considerations, most notable is particle
size of the inhaled drug, which determines the amount of
pulmonary deposition and, hence, the actual dose of a drug.
Pulmonary deposition factors differ among species and must
be considered in identifying the actual doses for the No
Observed Adverse Effect Level. These NOAELs are used to
determine safety margins for proposed doses in clinical
trials and whether studies in humans are considered safe to
proceed based on non-clinical study data.
Laryngeal squamous metaplasia in rats in inhalation
studies. Luqi Pei, Ph.D., Division of Pulmonary
and Allergy Drug Products, discussed the interpretation of
laryngeal squamous metaplasia in rats. This is a common
pathological finding in inhalation toxicity studies in the
species. The phenomenon appears to be an adaptive,
protective and species-specific response in rats. In most
cases, it carries little relevance in the non-clinical
safety evaluation of inhalation drug products in humans. The
presentation was informative to reviewers who do not
routinely evaluate inhalation toxicity studies now, but are
expected to review more of such studies in the future as the
inhalation route of administration gains popularity in drug
development.
Non-clinical studies for drugs administered by the
ocular route. Zhou Chen, Ph.D., Division of
Anti-Inflammatory, Analgesic and Ophthalmic Drug Products,
presented an overview of the specifics for non-clinical
studies required for ophthalmic drugs. He explained eye
structure and different ocular dosing routes. The need for
certain ocular toxicity data determines the type of animal
studies that need to be performed.
Dr. Chen addressed animal species selection and ocular
toxicity evaluation. He also discussed ophthalmic drug
formulation, dosing frequency, dosing volume and study
duration in ocular toxicity study design. While most ocular
drugs are applied to the eye, several drugs given orally may
have intended and unintended ocular effects.
Non-clinical safety assessments for intrathecal drug
products. Dan Mellon, Ph.D., Division of
Anesthetic, Critical Care and Addiction Drug Products,
explained the differences between epidural, intrathecal and
intraspinal dosing and associated relative absorption rates
and effectiveness. Although there are a number of drugs that
have been approved for epidural administration, there are
only a few drugs that have been approved by FDA for
intrathecal use. Intrathecal drugs are injected directly
into the spinal cord rather that epidurally into the fluid
surrounding the spinal cord.
Due to the sensitivity of the neurons in the spinal
column, the non-clinical safety assessment for drugs seeking
an epidural indication should characterize the inadvertent
administration of the drug product into the intrathecal
space. The non-clinical safety assessment for drugs seeking
a chronic epidural or intrathecal route of administration
has been limited by a the availability of adequate animal
models. Dr. Mellon also presented an example of clinical
studies inappropriately preceding adequate non-clinical
assessment.
The retreat started with opening remarks from Hanan
Ghantous, Ph.D., DABT, the chairperson of the meeting,
followed by true-false questions about FDA’s future home,
White Oak. One of the true statements was that, in 1995, an
explosive storage magazine exploded, causing limited damage
to some of the surrounding communities. Reviewers living
close to White Oak remember hearing the explosion.
The retreat was organized by pharm/tox reviewers and
staff from various divisions including Dr. Ghantous (chair),
Margot Brower, Ph.D., Dave Hawver, Ph.D., Steve Kunder,
Ph.D., Shwu-Luan Lee, Ph.D., Yanli Ouyang, Ph.D., DABT, Tom
Papoian, Ph.D., DABT, Adele Seifried, Suzanne
Thornton-Jones, Ph.D., and myself.
Gary Bond, a senior staff fellow in the Division of
Pulmonary and Allergy Drug Products, acknowledges the
assistance of the speakers and retreat committee members in
preparing these articles.
Return to Index
By Gary P. Bond, Ph.D., DABT
During the scientific retreat for pharm/tox reviewers, John
Jenkins, M.D., the director of the Office of New Drugs,
talked about:
-
The White Oak move.
-
The OND reorganization
-
ODE associate directors for
pharmacology and toxicology.
-
The quality systems approach to
processes and procedures
-
The Critical Path Initiative.
-
Screening INDs.
White Oak move
This will take place by about May of next year. The move
will provide an opportunity for revitalization, culture
change and consolidation of all our colleagues and resources
in a new facility in a community that is excited about our
arrival.
OND reorganization
No major changes are envisioned. The reorganization
will happen in a way that creates logical groupings in the
same divisions, creates divisions with better balanced
workloads and resource allocation, and completes the
integration of biologics reviewers and indications into
CDER.
ODE pharm/tox associate directors
These new positions form a critical part of the pharm/tox
discipline. The associate directors will emphasize such
things as education, recruitment, reviewer training and
consistency of reviews through tertiary reviews.
[Earlier during the retreat, Ken Hastings, Ph.D.,
DABT, the associate pharm/tox director for ODEs II and
III, had introduced Abby Jacobs, Ph.D., the associate
pharm/tox director for ODEs IV and V, and David Green,
Ph.D., the associate pharm/tox director for ODEs I and
VI. Dr. Hastings had also described the facilitator roles
expected of the associate directors.]
Dr. Jenkins emphasized that he expects everyone to
support the associate directors in their important support
function to OND. In response to another question related to
the associate director function, he noted that the tertiary
review of genotoxicity and carcinogenicity reviews creates
consistency and harmonization of OND’s recommendations and
decisions to the industry and the public, especially when
the decisions involve clinical holds.
Quality systems
This is a dynamic, transparent approach to processes
and procedures that defines staff function and
accountability and the mechanisms for improvement. Outside
contractors have done the systems assessment. Implementation
of the recommendations will be forthcoming. This is a good
thing, Dr. Jenkins asserted.
Critical Path Initiative
Janet Woodcock, M.D., acting deputy commissioner for
operations, has been very involved in this activity (above).
The initiative aims at promoting public health by
facilitating development of safe, effective drugs and
increasing public awareness of FDA’s role in transitional
and critical path research that moves drugs along from basic
research to and through the development process.
Screening INDs
These (above)
are still in policy development by OND and are an
important project in the critical path initiative. Dr.
Jenkins is considering the feasibility of a separate review
group for screening INDs, either dedicated or ad hoc, depending
on the workload.
Budget
In response to a question, Dr. Jenkins noted that the
budget is tight and will be tight, or at least flat. He said
that there are currently no hiring freezes on scientific
staff; however, staff ceilings must be managed.
Return to Index
:
Compliance’s Therapeutics Facilities Review Branch
keeps pace
By Patrick E. Clarke
"We haven’t missed a PDUFA date since I have been
here,” said Michael Smedley, branch chief of the
Therapeutics Facilities Review Branch, Division of
Manufacturing and Product Quality, which is in CDER’s
Office of Compliance. While Smedley is proud to be able to
make that statement, working long hours to keep up has
become commonplace in the branch. “This group is running
at 200 percent, and we’re ready to go to 100 percent,”
he said.
The branch, consisting of eight people, was part of the
transfer of therapeutic biologics to CDER in October 2003.
In December, Smedley came from the Center for Veterinary
Medicine to serve as acting branch chief and has been
permanently selected for the position.
“Shortly before I started, four senior
reviewers/investigators went back to CBER,” Smedley said.
“We ended up with two senior reviewers who were both
part-time employees, and two who still needed inspection
training.” Since then, one of that group has left the
federal government.
“We’ve had numerous employees come from within our
own Division of Manufacturing Product Quality in the Office
of Compliance for details and one from the Office of
Biotechnology Products,” Smedley said. “The detailees
have been invaluable and have helped keep us afloat, but it
takes a while for them to learn our processes. They
generally get productive toward the end of their 60-day
detail.”
The branch’s members have responsibilities in the
following areas:
-
Application review of transferred
therapeutic products.
-
Pre-submittal support for meetings
with industry.
-
Review of chemistry, manufacturing
and controls and establishment description.
-
Serving as facility inspection team
leaders.
-
Consulting on premarket reviews and
ensuring compliance with current good manufacturing
practices after approval.
-
Providing support functions,
including policy and guidance document development; cGMP
and inspection training; and industry presentations.
The work done by the branch is comprehensive, complex and
requires a good scientific understanding of the process. The
branch reviews the portion of the biologic license
application or supplement that deals with a facility. If a
pre-approval inspection for a BLA is needed, it is performed
by one of the branch’s reviewer-investigators as the lead
investigator. The reviewer’s tasks include review of
equipment, floor diagrams and classifications, environmental
assessments, the method of manufacture and packaging and an
entire section of checks regarding microbiology.
The Microbiology Section includes review of drug product
solution filtration, specifications concerning hold times,
critical aseptic operations, sterilization processes,
depyrogenation processes, aseptic process validation,
environmental monitoring, product component bioburden. “Many
of the CMC review responsibilities are shared with the
product office reviewer, Smedley said. “For example, for
the container/closure system we focus on integrity and
biocompatability studies while the product office review
stability of the drug substance in the container.”
Sometimes, a supplement to an application can require
almost as much work as an original application. “A prior
approval supplement could require multiple inspections, plus
all the paperwork, such as writing the inspection reports
and review of the submitted application. And companies are
constantly supplementing,” Smedley said.
During a prior-approval inspection, the reviewer becomes
an investigator and covers the following facility related
issues such as manufacturer identification, floor diagrams,
other products in multi-product areas, raw materials and
reagents, manufacturing flow charts, animal facility cGMP
issue and in-process controls, Smedley said.
The branch previously had regulatory project managers to
help coordinate the workload. “But our branch hasn’t had
any RPMs since the move to CDER,” Smedley said. “We have
scientists doing RPM work. It’s just not efficient.”
The branch also didn’t have a secretary until recently.
“We do have a secretary now for two days a week; although,
we share the secretary with another branch,” Smedley said.
“Employees have been working long hours and haven’t been
taking their vacations.”
Smedley’s own schedule has been brutal. “Often, the
review part of my day starts after 5 p.m., after reviewers
have turned in their submissions. I’m here for 4 to 5
hours after that. So, 12- to 14-hour days haven’t been
uncommon. Now that we have eight permanent reviewers in the
TFRB, things are starting to get back to normal,” Smedley
said.
“The Therapeutics Facilities Review Branch has survived
the transition from CBER to CDER. We have been able to put
together a highly qualified staff that is in the process of
integrating all aspects of their review and inspection
process into CDER. These individuals bring with them, strong
educational, industrial, scientific and FDA backgrounds. The
TFRB reviewers have all done an exceptional job.”
“But it takes about a year to train a reviewer and
possible two to three years to train as an investigator,
depending on the employees background,” Smedley said. “If
the INDs that are out there now turn into BLAs we could
easily be swamped. We don’t know if next year we’ll get
5 or 70 new ones.”
Smedley hopes the branch will grow in both efficiency and
personnel.
“For the future, we plan to add efficiencies to the
process and in line with the cGMPs for the 21st Century
Initiative will bring the best science to our reviews and
inspections,” Smedley said. “This growing segment of the
pharmaceutical industry will benefit and be able to use the
latest technologies for manufacturing, risked-based
approaches and continuously improve. We hope to continue to
grow beyond just one new employee but at least at a pace to
keep up with the exponential growth possible with the
biotech industry.”
Return to Index
In March, FDA revised a long-standing policy document
regarding the validation of pharmaceutical manufacturing
processes for drugs that are subject to pre-market approval
requirements.
This is an important first step in the Agency’s plan to
address the area of process validation. The effort is being
taken in concert with FDA’s initiative on the regulation
of pharmaceutical quality known as “Pharmaceutical cGMPs
for the 21st Century: A Risk-Based Approach.”
New to this version are:
-
Recognition of the role of emerging
advanced engineering principles and control technologies
in ensuring batch quality. For drugs produced using
these new principles and technologies, this guidance
provides for possible exceptions to the need for
manufacturing multiple conformance batches prior to
initial marketing.
-
Deletion of the previous reference to
“three” validation (or conformance) batches at
commercial scale as adequate minimum proof of process
validity-a number is no longer suggested.
-
Further clarification of the
importance of post-market information gathering
especially for those batches released to market
concurrent with the manufacture of the initial
conformance batches.
As with the previous version, the new version reaffirms
that Agency drug product pre-market review units may approve
applications for marketing before a firm has manufactured
one or more conformance batches at commercial scale, also
sometimes referred to as “validation” batches.
The revised guidance again recognizes certain conditions
under which a firm may market batches of drugs while
gathering data to confirm the validity of the manufacturing
process.
More information is available on CDER’s Web site at http://www.fda.gov/cder/gmp/processvalidation.htm.
Return to Index
The nation’s leading cancer organizations have reported
that Americans’ risk of getting and dying from cancer
continues to decline. Also, survival rates for many cancers
continue to improve. The Annual Report to the Nation on
the Status of Cancer, 1975-2001 finds that death rates
from all cancers combined dropped 1.1 percent per year from
1993 to 2001. The overall observed cancer incidence rates,
or the frequency with which cancer occurs, dropped 0.5
percent per year from 1991 to 2001. The new data reflect
progress in prevention, early detection and treatment;
however, not all segments of the U.S. population have
benefited equally from the advances.
First issued in 1998, the report is a collaboration among
the American Cancer Society, the Centers for Disease Control
and Prevention, the National Cancer Institute and the North
American Association of Central Cancer Registries. It
provides updated information on cancer rates and trends in
the United States and features a special section on cancer
survival.
Death rates decreased for 11 of the top 15 cancers in men
and eight of the top 15 cancers in women. Lung cancer death
rates among women leveled off for the first time between
1995 and 2001, after continuously increasing for many
decades.
Cancer incidence rates among men, have recently declined
for seven of the top 15 cancer sites: lung, colon, oral
cavity, leukemia, stomach, pancreas and larynx. Incidence
rates in men increased for melanoma and cancers of the
prostate, kidney and esophagus.
For the first time, lung cancer incidence rates among
women are on the decline. Incidence rates decreased for five
additional cancers out of the top 15 in women: colon,
cervix, pancreas, ovary and oral cavity. Breast, thyroid,
bladder and kidney cancer, and melanoma rates are rising
among women.
Survival improvements noted
The report highlights trends in cancer survival by
comparing five-year survival rates of cancer patients
diagnosed in two time periods: 1975-1979 and 1995-2000.
Between those time periods, survival substantially improved
for most of the top 15 cancers in both men and women as well
as the top 10 sites in children.
For men, large gains in cancer survival rates (more than
10 percent) were seen in cancers of the prostate, colon and
kidney and non-Hodgkin lymphoma, melanoma and leukemia.
Modest gains (5 percent to 10 percent) were found for
cancers of the bladder, stomach, liver, brain and esophagus.
For women, large gains in cancer survival rates were seen
for colon, kidney and breast cancers and non-Hodgkin
lymphoma. Modest gains were found for bladder, oral cavity,
stomach, brain, esophageal and ovarian cancers and melanoma
and leukemia.
Limited survival improvement was noted for the most fatal
forms of cancer in adults including cancers of the lung,
pancreas and liver, which are characterized by late stage at
diagnosis and relatively poor survival rates even when these
cancers are diagnosed at a localized stage. There was also
little or no gain in several cancers that already have high
survival rates, including larynx, thyroid and uterine
cancers.
Childhood cancers showed some of the largest improvements
in cancer survival during the past 20 years, with an
absolute survival rate increase of 20 percent in boys and 13
percent in girls. The current five-year survival rate of
more than 75 percent confirms substantial progress made
since the early 1960s, when childhood cancers were nearly
always fatal.
The report is available online at
http://www.seer.cancer.gov.
Click on the icon “1975-2001 Report to the Nation.”
Return to Index
The Pike is published electronically
approximately monthly on the World Wide Web at: http://www.fda.gov/cder/pike.htm.
Photocopies are available in the Medical Library
(Parklawn Room 11B-40) and its branches (Corporate Boulevard
Room S-121 and Woodmont II Room 3001).
Views and opinions expressed are those of the authors and
do not necessarily reflect official FDA or CDER policies.
All material in the Pike is in the public domain and may be
freely copied or printed.
Pam Fagelson
Elaine Frost
Mary Jane Mathews
Edward Miracco
Melissa Moncavage
Ellen Shapiro
Ted Sherwood
Tony Sims
Nancy Smith
Wendy Stanfield
Marcia Trenter
Jennifer Wagner
Diane Walker
Grant Williams
Pamela Winbourne
Have ideas, news or comments to contribute?
Please contact a member
of the Editorial Board or:
News Along the Pike
CDER Office of Training and Communications
(HFD-210)
Parklawn Building, Room 12B-31
Editor: Norman
"Joe" Oliver (OLIVERN)
Associate Editors: Patrick Clarke, Christine
Parker
Phone: (301) 827-1695
Fax: (301) 827-3055
Return to Index
Back to Top
Back to
About CDER
Date created: July 15, 2004